Competitive Sport After Sars-Cov-2 Infection in Children

Giulia Cafero (giulia.cafero@gmail.com)
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu
https://orcid.org/0000-0001-6180-9338

Passi Falminia
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Francesca Ippolita Calò Carducci
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Gentili Federica
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Giordano Ugo
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Chiara Perri
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Melania Hashem Said
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Turchetta Attilio
Bambino Gesu Pediatric Hospital: Ospedale Pediatrico Bambino Gesu

Research

Keywords: INFECTION, coronavirus, COVID-19, adult

DOI: https://doi.org/10.21203/rs.3.rs-645000/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

With the gradual resumption of sports activities after the lock-down period, during coronavirus pandemic, a new problem is emerging: allow all athletes to be able to return to compete after SARS-CoV-2 infection in total safety. Several protocols have been proposed for healed athletes but all of them have been formulated for the adult population.

Methods

The aim of the present study is to evaluate the adequacy of Italian practical recommendations for return-to-paly, in order to exclude cardiorespiratory complications due to COVID-19 in children and adolescents. From September 2020 to February 2021, 45 children and adolescents (aged from 9 to 18 years) with previous SARS-CoV-2 infection were evaluated according to the protocols in force for adult.

Results

The data obtained showed that, in the pediatric population, mild coronavirus infection does not cause cardiorespiratory complications in the short and medium term.

Conclusion

Return to play after Coronavirus infection seems to be safe but it will be necessary to continue with the data analysis in order to modulate and optimize the protocols especially in the pediatric field.

Introduction

With the outbreak of the pandemic caused by SARS-CoV-2 in December 2019, global attention was immediately focused on the impact of the virus on the adult population. The epidemiological characteristics have led to think that the pediatric population may be less susceptible to coronavirus. The social distancing policies, strongly imposed in many countries, have significantly contributed to containing the spread of the virus. In particular, the interruption of school, sports and recreational activities have made it possible to protect children and adolescents from exposure to the virus.

The national data relating to the spread of the virus on the Italian national territory indicated, in June 2020, an incidence of 0.9% in the 0–9 age group and 1.6% in the 10–19 age group [1]. The progressive easing of social distancing measures has led to a progressive increase in the incidence of infection in the pediatric population over the following months (4% in the 0–9 years range; 8.4% in the 10–19 years range) with values in any case consistently lower than adults [2].
Despite the increased spread of the virus among the youngest, the prognosis continues to remain significantly better than in the adult population, with a significantly higher rate of asymptomatic or mild symptomatic infections compared to the older age groups [3].

However, it is known that patients with COVID-19 disease may present cardiac involvement with a broad spectrum of clinical manifestations (due to the presence of angiotensin-converting enzyme 2 receptors) [4]. In the literature, the presence of myocardial damage is also described in the absence of symptoms, and cardiac complications can include heart failure, cardiac arrhythmias and sudden death [5].

These evidences have pushed the formulation of comprehensive strategies to ensure a safe return to training and competition for all the athletes [6].

So far there are few data concerning pediatric population; available protocols for a safe return to play concern only adults.

In April 2020, in compliance with the regulations for national health prevention [7], protocols dedicated to professional athletes (PA) [8] were published and subsequently reworked to be applied to all athletes (A) engaged in sports at competitive level [9]. (Fig. 1).

The purpose of this study is to evaluate the application of Italian cardiopulmonary protocols for return to competitive sport after SARS-CoV-2 infection to a pediatric population.

**Methods**

**3.1 Study desing**

From October 2020 to February 2021, pediatric patients recovered from coronavirus infection were evaluated according to the protocols in force: the first 17 control patients were evaluated according the PA protocol; the next 28 patients were evaluated according to the revised protocols applied to all athletes (A), not just professionals.

Inclusion criteria: age less than 18 years; previous SARS-CoV-2 infection documented by polymerase chain reaction on a nasopharyngeal swab; negativity for at least 30 days; patients practicing competitive sports.

Exclusion criteria: non-cooperating patients for functional tests due to age and/or psycho-physical limitations; patients with a negative swab for less than 30 days; symptomatic patients (cough, cold, fever); patients with a history of congenital heart disease even if corrected and cured; patients with a positive history of hyper or hypokinetic arrhythmias; patients with bronchial asthma.

It was also decided to exclude one patient with Multi-System Inflammatory Syndrome in Children (MIS-C) as this case was included in a different study protocol.
For all patients we described demographic data, duration of infection, severity of symptoms according to NIH classification [10].

All patients were subjected to a serological test to rule out any false positives.

Blood chemistry tests, including markers of myocardial damage, were performed only in PA group.

All patients underwent an echocardiographic evaluation with determination of the ejection fraction.

Patients in PA protocol underwent a symptom-limited cardiopulmonary exercise test (CPET) using a treadmill, following the modified Bruce protocol with continuous 12-lead electrocardiographic monitoring system.

Data collected during cardiopulmonary test included: respiratory quotient (RQ), the peak of VO2 consumption during the test (Peak VO2, defined as the average value in the last 20 seconds of the effort in relative –ml/kg/min-values) and the ratio between ventilation and exhaled carbon dioxide (VE/VCO2).

We considered the test as maximal when subjects reached at least RQ > 1 and we used for VO2max and VE/VCO2 ratio the cut-off suggested by Takken et al. [11]: a VO2max > 50 mL/kg/min has been considered as normal, 40–50 mL/kg/min good, 20–40 reduced; 35 was considered the cut-off for VE/VCO2 ratio.

A standard 24 h Holter ECG monitoring was performed in this group.

Patients in A protocol underwent a maximal exercise test using a treadmill, following the modified Bruce protocol with continuous 12-lead electrocardiographic monitoring system.

We considered the test as maximal when the heart rate reached at least 85% of the theoretical value for age.

Desaturation during effort was considered as losing 4 or more point of blood oxygen saturation.

Systolic blood pressure was also obtained at baseline (BP), during and at the end of exercise (BP max).

Lung function was measured by conventional spirometry; Forced Vital Capacity (FVC) and Forced Expiratory Volume at the 1st second (FEV1) were expressed as percentage of predicted values [12].

In the PA group, although not required by the protocols, lung diffusion capacity for carbon monoxide (DLCO) was also assessed, measured by means of the single-breath test. The hemoglobin value was taken for correcting the DLCO. Measurements were expressed as percentages of predicted normal values. Diffusion deficit was considered as DLCO < 80% of predicted value.

All pulmonary function test was performed according to the protocols for the prevention of coronavirus disease [13].
3.2 Data analysis

Continuous variables were described using mean with standard deviation (SD) and compared with unpaired Student’s t-test, if normally distributed, or with Mann-Whitney U test, if not normally distributed. Categorical variables were reported as frequencies and compared with Chi-square test.

A p value of < 0.05 was considered statistically significant. All statistical analyses were performed using MedCalc Statistical Software version 15.8 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2015).

Results

4.1 Patients characteristics

A total of 45 patients were enrolled: 17 in PA group (M = 13); 28 in A group (M = 13).

The mean age of the patients analyzed was 13.97 ± 1.9 years.

Data on negative swab times and data on symptoms were collected retrospectively during clinical evaluation: the mean negative time for nasal swabs was 18 ± 2.7 days; 25 subjects reported being asymptomatic; 14 subjects reported fever lasting no more than 4 days; anosmia was reported in 6 cases.

4.2 Functional data

Complete data of the analyzed population are reported in Table 1.
Table 1
Functional parameters

|            | RESULTS        |
|------------|----------------|
| FEV1       | 97,9 (11,5)    |
| FVC        | 94,6 (12,4)    |
| VO2/MAX (ml/kg/min) | 41,6 (7,8)   |
| VE/VCO2    | 29,5 (4,7)     |
| RQ         | 1,06 (0,1)     |
| DLCO       | 91,5 (15,7)    |
| EF%        | 65,9 (4,2)     |

Data expressed as mean (standard deviation)

FVC = forced vital capacity; FEV1 = Forced Expiratory Volume in the 1st second; RQ = respiratory quotient; DLCO = diffusion capacity of the lung for carbon monoxide; EF = ejection fraction

At cardiovascular level, all patients obtained results that could be correlated with the current state of training and no new case of arrhythmias were found.

On patient showed arterial hypertension. Before being able to correlate the hypertension to the infection, the patient is carrying out the study to exclude secondary causes.

All the examinations to assess pulmonary function were found to be within the normal limits.

4.3 Blood parameters

All blood chemistry tests, including markers of myocardial damage, were found within the reference values.

Discussion

The SARS-CoV-2 pandemic has profoundly affected all aspects of daily life and has not spared any age group.

While in the first wave the severe restrictive measures meant that the youngest were just touched by this virus, during the following waves the pediatric-adolescent age saw an increase in the rate of infections. It was therefore essential, before the restart of any activity, including sports, to check the impact of the virus on the health of those recovered from the infection. Several protocols have been formulated to investigate short and medium-term complications on the different organs and systems involved in the infection. The role of ACE-2 receptors in the pathogenesis of the disease is now known [14] and since this receptor is not
only present in the lungs but also in the heart, kidney, vascular and intestinal areas, it was essential not to underestimate any theoretical complication.

In Italy, since April 2020, strict protocols have been applied for the evaluation of professional athletes before resuming physical activity after coronavirus infection. As the months went by and the gradual reopening, the protocols have been revised to be suitable for the entire population of athletes practicing competitive sports. Young people necessarily also fall into these categories.

The data collected in recent months at our institute on a pediatric population (aged 9 to 18 years) made it possible to assess the impact of SARS-CoV-2 infection mainly at respiratory and cardiovascular level. As shown by the results, most patients had an asymptomatic or mild symptoms infection. At the end of our observation period in February 2021, only 1 subject was diagnosed with MIS-C. Having subsequently noted a slight increase in MIS-C cases, it was therefore preferred to exclude this patient and enroll it in a dedicated study currently underway.

No short or medium term complications were observed, either cardiovascular or respiratory. Our data, although preliminary and collected on a selected pediatric population, do not differ from the data currently available in the literature [15]. In relation to the impact of the pandemic on global public health, it was essential to apply the protocols in force before the resumption of sporting activities at a competitive level.

**Conclusion**

The results of the present study make us state that, in the case of mild coronavirus infection, pediatric population is not at risk of developing cardio-respiratory complications even under high physical stress conditions.

The main limitation of this study concerns the sample size, however reflecting the incidence of infection in this age group.

Children and adolescents will continue to be assessed before resuming sporting activity, in order to confirm data obtained until now, by progressively including subjects affected by MIS-C.

It will therefore be possible to assess the possibility of lightening or even suspending these evaluations in the cases of mild coronavirus infection in the pediatric age groups.

**Declarations**

**Ethics approval and consent to participate:** the study was regularly notified to the Ethics Committee. No investigation has been carried out unless provided for by the law currently in force in Italy.

**Consent for publication:** informed consent to participate in the study has been obtained from participants (or their parent or legal guardian in the case of children under 18)
Availability of data and materials: The data analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: The study is the result of the analysis of clinical data. no research funds were needed.

Authors’ contributions: CG: patient selection, obtaining informed consent, protocol application, data verification, text processing. PF: statistic analysis. CCF: infectious disease evaluation. GF: patient selection, revision of the text. GU: ergometry execution. PC and HSM: echocardiographic evaluation. TA: execution of lung function tests and cardiopulmonary tests, revision of the text.

Acknowledgements: Not applicable

References

1. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_16-giugno-2020.pdf
2. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_27-gennaio-2021.pdf
3. Jonas F, Ludvigsson. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr Actions. 2020 Jun;109(6):1088–95. doi:10.1111/apa.15270. Epub 2020 Apr 14.
4. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? [published online ahead of print, 2020 Mar 24]. JAMA. 2020;10.1001/jama.2020.4812.
5. Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, Rabbani L, Brodie D, Jain SS, Kirtane AJ, Masoumi A, Takeda K, Kumaraiah D, Burkhoff D, Leon M, Schwartz A, Uriel N, Sayer G. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020;141(23):1930. Epub 2020 Apr 3.
6. Baggish A, Drezner JA, Kim J, Martinez M, Prutkin JM. Resurgence of sport in the wake of COVID-19: cardiac considerations in competitive athletes [published online ahead of print, 2020 Jun 19]. Br J Sports Med. 2020;bjsports-2020-102516.
7. Decree of the Ministry of Health, February 18. 1982: Regulations for the health protection of competitive sporting activities (Publication in the Official Gazette, March 5, 1982, n. 63).
8. Casasco M, Galli M, Memo M, Pecorelli S, Pigozzi F, Signorelli C. Villani A. FMSI protocols for the resumption of sports activity in athletes. Italian Sports Medicine Federation, 30 Apr.2020.
9. Eligibility for competitive. sports activity in non-professional Covid-19 positive healed athletes and in athletes with symptoms suggestive of Covid-19 in the absence of SARS-CoV-2 diagnosis. 0001269-13/01/2021-DGPRE-MDS-P.
10. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
11. Takken T, Bongers BC, Van Brussel M, and E. H. J. Hulzebos, Pediatric norms for cardiopulmonary exercise testing - In relation to sex and age. 2014.
12. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J. Multi-ethnic reference values for spirometry for the 3–95 year age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.
13. Bignamini E, Cazzato S, Cutrera R, Ferrante G, La Grutta S, Licari A, Lombardi E, Midulla F, Piacentini G, Pifferi M, Santamaria F, Tancredi G, Turchetta A. Italian pediatric respiratory society recommendations on pediatric pulmonary function testing during COVID-19 pandemic. Ital J Pediatr. 2020 May;24(1):68. doi:10.1186/s13052-020-00829-0.
14. Wenhui Li MJ, Moore N, Vasilieva J, Sui SK, Wongs MA, Berne M, Somasundaran JL, Sullivan K, Luzuriaga, Thomas C, Greenough. Hyeryun Choe, Michael Farzan. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
15. Al-Sadeq DW. G. K. Nasrallah. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review. Int J Infect Dis Actions. 2020 Sep;98:372–80.

**Figures**

**Figure 1**

return to play protocol after COVID infection